10-mg tabVTE prevention in knee replacement 10 mg once daily 6-10 hr post-op. Duration of therapy: 14 days. VTE prevention in hip replacement 10 mg once daily 6-10 hr post-op. Duration of therapy: 35 days. Geriatric Adult dose. 15- & 20-mg tabPrevention of stroke & systemic embolism 20 mg once daily. Max daily dose: 20 mg. DVT & PE Initially 15 mg bid for 21 days followed by 20 mg once daily. Recommended max daily dose: 30 mg during 1st 3 wk, then 20 mg in the following treatment phase. Prevention of recurrent DVT & PE 20 mg once daily. Non-valvular atrial fibrillation Renal impairment CrCl 15-50 mL/min 15 mg once daily.
View Rivoxan overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: May be crushed & mixed in 50 mL of water for nasogastric/gastric feeding tube administration w/in 4 hr of preparation.
Contraindications
Hypersensitivity. Clinically significant active bleeding eg, intracranial & GI bleeding. Hepatic disease associated w/ coagulopathy leading to clinically relevant bleeding risk. Pregnancy & lactation.
Discontinue in patients who develop acute renal failure (CrCl <15 mL/min); if INR falls to <3; at least 24 hr prior to surgery/invasive procedures or 3 days prior in patients w/ CrCl ≥50 mL/min or 5 days prior if CrCl <50 mL/min. Major hemorrhages eg, intracranial, GI, epidural hematoma, adrenal bleeding. Spinal or epidural hematomas w/ neuraxial anesth (epidural or spinal anesth) or spinal puncture in patients who are anticoagulated; may result in long-term or permanent paralysis. Increased risk of thrombotic events including stroke. Avoid use in patient w/ CrCl <30 mL/min. Concomitant use w/ drug therapy known to increase systemic exposure & deteriorates renal function. Moderate to severe hepatic impairment (Child-Pugh class B & C) or hepatic disease associated w/ coagulopathy. Moderate renal impairment (CrCl 30-50 mL/min). Avoid use in severe renal impairment. Pregnancy & lactation. Elderly.
Sign Out
